motesanib + paclitaxel

**Motesanib (AMG 706) + paclitaxel** is an investigational combination therapy evaluated in several phase II and III trials for advanced cancers, including non-small cell lung cancer and breast cancer. Motesanib is an orally administered small molecule that acts as an antagonist to multiple receptor tyrosine kinases, including **vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1/2/3)**, **platelet-derived growth factor receptors (PDGFR)**, and **stem cell factor receptor (c-KIT)**. Paclitaxel is a chemotherapy drug that stabilizes microtubules, thereby inhibiting cell division. Motesanib is developed to target tumor angiogenesis, while paclitaxel targets cell proliferation. The combination was not shown to significantly improve progression-free survival or overall survival compared to chemotherapy alone, and development has been discontinued for multiple indications following lack of efficacy and safety concerns, including serious adverse events like posterior reversible encephalopathy syndrome[1][2][3][5][6][7].

Brand names

None

Other names

motesanib + paclitaxelAMG 706 + paclitaxel